Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$3.77 USD
+0.04 (1.07%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $3.76 -0.01 (-0.27%) 7:28 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Arbutus Biopharma Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 18 | 39 | 11 | 7 | 6 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 18 | 39 | 11 | 7 | 6 |
Selling & Adminstrative & Depr. & Amort Expenses | 96 | 104 | 85 | 64 | 150 |
Income After Depreciation & Amortization | -78 | -65 | -74 | -57 | -144 |
Non-Operating Income | 6 | 2 | 0 | -2 | -20 |
Interest Expense | 0 | 2 | 3 | 4 | 2 |
Pretax Income | -73 | -65 | -76 | -64 | -166 |
Income Taxes | 0 | 4 | 0 | 0 | -13 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -73 | -69 | -76 | -64 | -154 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -73 | -69 | -76 | -64 | -154 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -77 | -64 | -72 | -55 | -76 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 2 | 2 | 68 |
Income After Depreciation & Amortization | -78 | -65 | -74 | -57 | -144 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 165.96 | 150.94 | 106.24 | 75.84 | 57.09 |
Diluted EPS Before Non-Recurring Items | -0.44 | -0.46 | -0.83 | -1.00 | -1.62 |
Diluted Net EPS (GAAP) | -0.44 | -0.46 | -0.83 | -1.00 | -2.89 |
Fiscal Year end for Arbutus Biopharma Corporation falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 1.73 | 1.53 | 2.15 | 4.66 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 1.73 | 1.53 | 2.15 | 4.66 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 23.31 | 20.89 | 22.89 | 26.22 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -21.58 | -19.36 | -20.74 | -21.56 |
Non-Operating Income | NA | 1.82 | 1.53 | 1.48 | 1.50 |
Interest Expense | NA | 0.03 | 0.04 | 0.04 | 0.05 |
Pretax Income | NA | -19.80 | -17.88 | -19.31 | -20.10 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -19.80 | -17.88 | -19.31 | -20.10 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -19.80 | -17.88 | -19.31 | -20.10 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 188.04 | 175.63 | 160.93 | 167.51 |
Diluted EPS Before Non-Recurring Items | NA | -0.11 | -0.10 | -0.12 | -0.12 |
Diluted Net EPS (GAAP) | NA | -0.11 | -0.10 | -0.12 | -0.12 |